Surface modified anticancer nanoparticles

  • US 5,399,363 A
  • Filed: 07/01/1992
  • Issued: 03/21/1995
  • Est. Priority Date: 01/25/1991
  • Status: Expired due to Term
First Claim
Patent Images

1. Particles consisting essentially of 99.9% by weight of a crystalline medicament useful in treating cancer susceptible to treatment with said medicament, said medicament having a solubility in water of less than 10 mg/ml, and having a non-crosslinked surface modifier adsorbed on the surface thereof in an amount of 0.1-90% by weight and sufficient to maintain an average effective particle size of less than 1000 nm, wherein said medicament is selected from the group consisting of alkylating agents selected from the group consisting of alkylating agents having a bis-(2-chloroethyl)-amine group, alkylating agents having a substituted aziridine group, alkyl sulfonates, and N-alkyl-N-nitrosoureas;

  • antimetabolites;

    natural products selected from the group consisting of vinca alkaloids, epipophylotoxins, adriamycine, daunomycine, doctinomycine, daunorubicin, doxorubicin, mithramycin, bleomycin, mitomycin, enzymes, biological response modifiers, camptothecin, taxol and retinoids;

    hormones and antagonists;


    platinum coordination complexes;

    anthracenediones; and

    adrenocortical suppressants.

View all claims

    Thank you for your feedback